Streetbeat News

Regulatory

NVO

The European Medicines Agency's Committee for Medicinal Products for Human Use recommended marketing authorization for Novo Nordisk's Awiqli, a once-weekly basal insulin icodec, for diabetes in adults. This recommendation is a significant step towards the commercialization of Awiqli in Europe, potentially improving diabetes management for patients.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 4:50 pm

USO

Houthi officials have assured China and Russia that their vessels will be safe passing through the Red Sea, according to a senior Houthi official speaking to Reuters. This development could impact the global oil supply routes and market perceptions.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 4:40 pm

RKDA

Arcadia Biosciences has received a Notice of Allowance for its US Patent Application 17/402,216, which focuses on plants with reduced lipase 1 activity for improved shelf-life, stability, rancidity, and flavor of plant products.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 4:23 pm

EIS

USO

Israel's Mossad Chief, Barnea, is set to visit Qatar on Friday to meet with mediators in an effort to secure a hostage deal, according to Reuters.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 4:18 pm

AYRWF

CCHWF

JUSHF

MSOS

STHZF

Vice President Harris has urged the DEA to expedite the rescheduling of cannabis, a move analyzed by Zuanic & Associates as a potential turning point in national drug policy. The report covers implications of rescheduling, FDA oversight, and the effects on the cannabis industry, including banking access and stock exchange listings. Pablo Zuanic predicts a 51% chance of DEA rescheduling cannabis, which previously spurred a market surge, notably benefiting the MSOS ETF and companies like StateHouse, Columbia Care, Jushi, and AYR Wellness.

Portfolio Pulse from Nicolás Jose Rodriguez

March 21, 2024 | 3:47 pm

AAPL

GOOG

GOOGL

META

Apple and Google are expected to be the first companies investigated under the EU's new Digital Markets Act, with Meta also anticipated to face scrutiny. This clampdown on Big Tech could lead to significant fines for the companies involved.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 3:39 pm

AAPL

Apple Inc (NASDAQ:AAPL) shares fell by 3.3% after the U.S. Department of Justice (DOJ) filed a lawsuit against the company, accusing it of monopolizing the smartphone market. The DOJ, along with 16 state attorneys general, alleges that Apple's practices have harmed consumers and developers by violating antitrust laws. Apple responded, arguing that the lawsuit misunderstands its business and could hinder its ability to innovate. This legal action follows similar suits against other major tech companies like Alphabet, Meta Platforms, and Amazon.

Portfolio Pulse from Adam Eckert

March 21, 2024 | 3:35 pm

Zillow's stock is trading higher, potentially recovering from a recent dip caused by a National Association of Realtors (NAR) ruling. The uptick may also be attributed to positive US existing home sales data.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 3:27 pm

COIN

Coinbase Inc. (NASDAQ:COIN) UK CEO Daniel Seifert highlighted Bitcoin as a viable financial alternative in challenging economies, citing regulatory advancements and the anticipation of Bitcoin's halving event as key growth drivers. Seifert emphasized the role of Bitcoin ETFs in boosting investor confidence and noted the growing mainstream acceptance of digital currencies. He also discussed the potential of Bitcoin in emerging markets, the importance of regulation for the crypto industry's future, and addressed misconceptions about Bitcoin mining's energy consumption.

Portfolio Pulse from Murtuza Merchant

March 21, 2024 | 3:09 pm

ARGX

JNJ

RHHBY

Argenx SE (NASDAQ:ARGX) shares surged due to Chugai Pharmaceutical's disappointing gMG trial results, boosting Argenx's market cap to $21.2 billion. Argenx's Vyvgart Hytrulo was FDA approved in June 2023 for gMG in adults, contributing to $1.2 billion in FY2023 revenues. Chugai's Enspryng failed to meet expectations in its Phase 3 LUMINESCE study for gMG, despite being developed with Roche Holdings AG (OTC:RHHBY). Johnson & Johnson (NYSE:JNJ) reported success in its Phase 3 VIVACITY study of nipocalimab for gMG.

Portfolio Pulse from Vandana Singh

March 21, 2024 | 3:06 pm